Semaglutide (Ozempic/Wegovy) shows 3-year efficacy for blood sugar control and weight loss

Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up to 3 years in adults. The findings were released on Oct 2, 2023 from the Annual Meeting of The European Association for the Study of Diabetes (EASD). “Our long-term analysis of semaglutide […]

New analysis of trial of semaglutide in adolescents shows it can reduce liver enzymes indicative of liver damage

A new substudy of the STEP TEENS trial presented at this year’s European Congress on Obesity (ECO 2023, Dublin 17-20 May) shows that adolescents using semaglutide experienced significant reductions in levels of liver enzymes that are an indicator of liver damage. The study is by Dr Daniel Weghuber, Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria, and Dr Rasmus Sørrig, […]

Semaglutide leads to significant weight loss in Type 2 diabetes patients

Article by Bruce Sylvester. Patients diagnosed with type 2 diabetes and treated with weekly semaglutide have achieved an average weight loss of almost 10kg, researchers reported on March 2, 2021  in The Lancet. Put in other terms, two-thirds of subjects treated with weekly injections of a 2.4mg semaglutide lost at least 5% of their body weight and achieved significant improvement in […]

Semaglutide reduces excess body fat in people with obesity

In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass, according to an industry-sponsored study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting. “Our findings suggest that semaglutide, through body weight loss and improvement of body composition, has the potential […]